In recent decades, targeted therapies based on oncogenic driver mutations or fusion proteins (i.e., EGFR and anaplastic lymphoma kinase (ALK)) have increased the overall survival and changed the treatment paradigm of NSCLC (comprising lung adenocarcinoma, lung squamous cell carcinoma, and lung large cell carcinoma)57. This evidence concerns the gene ALK and lung adenocarcinoma.